2014-04-22 15:26:41 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Vertex Pharmaceuticals Incorporated (VRTX) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Vertex Pharmaceuticals Incorporated (VRTX). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Vertex Pharmaceuticals Incorporated investor.
Report Summary: Vertex Pharmaceuticals Incorporated is a below average quality company with a neutral outlook. Vertex Pharmaceuticals Incorporated has strong business growth and is run by inefficient management. The trend in Vertex Pharmaceuticals Incorporated fair value exchange rate against its closest rated-competitor, XenoPort, Inc., has been appreciating over the past 2 weeks. When compared to its closest competitor, Vertex Pharmaceuticals Incorporated shows similar overvaluation and is equally likely to underperform the market.
The report breaks down the Total StockMark into its three
components - business, management and price, performing an in-depth analysis of Vertex Pharmaceuticals Incorporated for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext and from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, One source West Services, and Dow Jones/Factiva.
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering 31 different markets and over 22,000 companies. The StockMarks rating system is based on proven investment principles and is designed to drive long-term shareholder returns.